Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.55 |
| ▸ | KDM1A | O60341 | 3/20 | 0.54 |
| ▸ | APLNR | P35414 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | KDM5A | P29375 | 1/20 | 0.51 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.50 |
| ▸ | REN | P00797 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30844394 | 0.88 | KDM1A (0.58) | MAPK8MAPK9MAPK10KDM1AMAOB | |
| SCHEMBL30844413 | 0.87 | KDM1A (0.57) | MAPK8MAPK9MAPK10KDM1AMAOB | |
| SCHEMBL30844384 | 0.87 | KDM1A (0.57) | MAPK8MAPK9MAPK10KDM1AMAOB | |
| SCHEMBL30844380 | 0.87 | MAPK8 (0.55) | MAPK8MAPK9MAPK10KDM1AMAOB | |
| SCHEMBL30381351 | 0.87 | KDM1A (0.57) | MAPK8MAPK9MAPK10KDM1AMAOB | |
| SCHEMBL30844399 | 0.87 | KDM1A (0.56) | MAPK8MAPK9MAPK10KDM1AMAOB | |
| SCHEMBL30844374 | 0.86 | KDM1A (0.55) | MAPK8MAPK9MAPK10KDM1AMAOB | |
| SCHEMBL30844393 | 0.86 | KDM1A (0.55) | MAPK8MAPK9MAPK10KDM1AMAOB | |
| SCHEMBL30844339 | 0.86 | KDM1A (0.55) | MAPK8MAPK9MAPK10KDM1AMAOB | |
| SCHEMBL30311519 | 0.86 | MAPK8 (0.60) | MAPK8MAPK9MAPK10KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570697-B2 | Cyclic peptide useful in the treatment of cancer | SYNTHERIX LIMITED (GB) | 2026-03-10 | — | — | US | disclosed |
| EP-3947418-B1 | PEPTIDES AND USE THEREOF | SYNTHERIX LTD (GB) | 2024-04-03 | — | — | EP | disclosed |
| US-20220242914-A1 | PEPTIDES AND USE THEREOF | SYNTHERIX LIMITED (GB) | 2022-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570697-B2 | Cyclic peptide useful in the treatment of cancer | NPR1, NPR3, PTMS | MAPK8 1916/4885MAPK9 1702/4885MAPK10 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.